Diaceutics PLC announced an important and innovative upgrade to its DXRX platformwhichsees the Company's DXRX Signal productnowproviding alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers witheven more timely data to identifypatients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved.

DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases.

DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients. Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success.

This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients.